AEterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at American Chemical Society National Meeting
Published: Aug 13, 2012
|Poster #46:||"Dual PI3K/Erk Inhibitor AEZS-136, A Potent Anti-Tumor Compound Under Preclinical Development ", M. Gerlach, I. Seipelt, L. Blumenstein, K. Jung, T. Schuster, G. Mueller, E. Guenther, J. Engel and M. Teifel.|
|Session:||General poster session / division of medicinal chemistry;|
|Dates and time:||
Sunday, August 19, 2012 from 7pm to 9pm (Eastern); and|
Monday, August 20, 2012 from 8pm to 10pm (Eastern);
|Venue:||Pennsylvania Convention Center, Hall D|
AEZS-136 is an integral part of the Company's kinase research program comprising the investigation of different compounds for single Erk inhibition, single PI3K inhibition and dual Erk/PI3K kinase inhibition. AEZS-136 selectively inhibits the kinase activity of Erk 1/2 and class 1 PI3Ks, enabling simultaneous inhibition of the Raf-Mek-Erk and the PI3K-Akt signaling cascades. AEZS-136 was discovered using the Company's proprietary compound library and high throughput screening technology.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.